SABS Stock — SAB Biotherapeutics Inc.: Cash, EV, Pipeline

Share price

$3.51

Market cap

$319.4M

Cash

$102.6M

Enterprise value

$216.8M

Balance sheet

Cash	$102.6M
Debt	$0.0M
Net cash	$102.6M
Enterprise value	$216.8M
Basic shares	83.5M shares
Fully diluted shares	141.9M shares
Fully diluted market cap	$498.0M
Cash per share	$1.23

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SABS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2027 - Jan 24, 2028	High Dose SAB-142	Phase 2	Type 1 Diabetes	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SAB-142

Phase 2 · Active Modality: biologic (multi-specific, fully human anti-thymocyte globulin, redosable immunotherapy)

Target multiple immune cells/T lymphocytes

Indications

Stage 3 autoimmune type 1 diabetes (new onset) (Phase 2)

Catalysts

— second half of 2027

Status note Wholly owned lead candidate. Registrational Phase 2b SAFEGUARD study initiated Q3 2025, first patient dosed December 2025, actively enrolling and dosing across the U.S., EU, UK, Australia and New Zealand. Company confirmed with FDA in May 2025 its intent to use SAFEGUARD data as primary evidence for future BLA. Phase 1 in healthy volunteers and T1D patients reported topline results January 2025 and December 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	High Dose SAB-142
Lead indication	Type 1 Diabetes
Lead phase	Phase 2
Active trials	2
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07187531	Phase 2	Recruiting	Sponsor	SABS	—	Type 1 Diabetes	—
NCT06435936	Phase 1	Active, not recruiting	Sponsor	SABS	—	PHA1A	—
NCT07670650	Phase 3	Not yet recruiting	Collaborator	University of Florida	—	Type 1 Diabetes (T1D)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for SAb Biotherapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

SABS — SAB Biotherapeutics Inc.